supported by the National Natural Science Foundation of China(82225021);the National Key R&D Program of China(2022YFC2303403,2021YFA1300803,2021YFA1301404).
Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is continuously evolving since 2019.Some monoclonal antibodies(mAbs)have been developed and widely used,such as etesevimab(CB6)developed by Eli-Lilly/Junshi.H...
supported by the Key Project of applied basic research in Yunnan Province(202401AS070049);CAMS Innovation Fund for Medical Sciences(2021-I2M-1-038,2022-I2M-CoV19-002);National Key R&D Program of China(2021YFC230170402);Yunnan Key R&D Project(202103AQ100001).
Variants of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)continue to emerge and evade immunity,resulting in breakthrough infections in vaccinated populations.There is an urgent need for the development o...
funded by the National Key R&D Program of China(2023YFC2605302).
Objective The present study aimed to evaluate the immunogenicity of BA.2 variant receptor binding domain(RBD)recombinant protein formulated with CpG 1826 plus alum dual adjuvant.Methods The BA.2 variant RBD(residues 3...